These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 23100499)

  • 41. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.
    Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE
    Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients.
    Chen X; Li R; Ge S; Li Y; Cai C; Weng T; Zhang Y; Jiang J; Feng Z; Chen Y; Zhang Y; Ma J; Persing DH; Chen J; Tang YW; Sun F; Zhang W
    J Clin Microbiol; 2023 Jun; 61(6):e0183222. PubMed ID: 37249422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
    Fregonese F; Ahuja SD; Akkerman OW; Arakaki-Sanchez D; Ayakaka I; Baghaei P; Bang D; Bastos M; Benedetti A; Bonnet M; Cattamanchi A; Cegielski P; Chien JY; Cox H; Dedicoat M; Erkens C; Escalante P; Falzon D; Garcia-Prats AJ; Gegia M; Gillespie SH; Glynn JR; Goldberg S; Griffith D; Jacobson KR; Johnston JC; Jones-López EC; Khan A; Koh WJ; Kritski A; Lan ZY; Lee JH; Li PZ; Maciel EL; Galliez RM; Merle CSC; Munang M; Narendran G; Nguyen VN; Nunn A; Ohkado A; Park JS; Phillips PPJ; Ponnuraja C; Reves R; Romanowski K; Seung K; Schaaf HS; Skrahina A; Soolingen DV; Tabarsi P; Trajman A; Trieu L; Banurekha VV; Viiklepp P; Wang JY; Yoshiyama T; Menzies D
    Lancet Respir Med; 2018 Apr; 6(4):265-275. PubMed ID: 29595509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study.
    Lee EG; Min J; Kang JY; Kim SK; Kim JW; Kim YH; Yoon HK; Lee SH; Kim HW; Kim JS
    BMC Infect Dis; 2020 Jun; 20(1):446. PubMed ID: 32576154
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
    Patil SB; Tamirat M; Khazhidinov K; Ardizzoni E; Atger M; Austin A; Baudin E; Bekhit M; Bektasov S; Berikova E; Bonnet M; Caboclo R; Chaudhry M; Chavan V; Cloez S; Coit J; Coutisson S; Dakenova Z; De Jong BC; Delifer C; Demaisons S; Do JM; Dos Santos Tozzi D; Ducher V; Ferlazzo G; Gouillou M; Khan U; Kunda M; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moreau M; Moschioni M; Nahid P; Osso E; Oyewusi L; Panda S; Pâquet A; Thuong Huu P; Pichon L; Rich ML; Rupasinghe P; Salahuddin N; Sanchez Garavito E; Seung KJ; Velásquez GE; Vallet M; Varaine F; Yuya-Septoh FJ; Mitnick CD; Guglielmetti L
    Trials; 2023 Nov; 24(1):773. PubMed ID: 38037119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.
    Harausz EP; Garcia-Prats AJ; Law S; Schaaf HS; Kredo T; Seddon JA; Menzies D; Turkova A; Achar J; Amanullah F; Barry P; Becerra M; Chan ED; Chan PC; Ioana Chiotan D; Crossa A; Drobac PC; Fairlie L; Falzon D; Flood J; Gegia M; Hicks RM; Isaakidis P; Kadri SM; Kampmann B; Madhi SA; Marais E; Mariandyshev A; Méndez-Echevarría A; Moore BK; Nargiza P; Ozere I; Padayatchi N; Ur-Rehman S; Rybak N; Santiago-Garcia B; Shah NS; Sharma S; Shim TS; Skrahina A; Soriano-Arandes A; van den Boom M; van der Werf MJ; van der Werf TS; Williams B; Yablokova E; Yim JJ; Furin J; Hesseling AC;
    PLoS Med; 2018 Jul; 15(7):e1002591. PubMed ID: 29995958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of resistance to fluoroquinolones and injectable drugs among antituberculosis drugs by allele-specific primer extension on a microsphere-based platform.
    Kim K; Yang JS; Choi HB; Lee SH
    J Microbiol Methods; 2018 Jan; 144():111-116. PubMed ID: 29129484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.
    Liu CH; Li L; Chen Z; Wang Q; Hu YL; Zhu B; Woo PC
    PLoS One; 2011 Apr; 6(4):e19399. PubMed ID: 21559362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Resistance patterns among drug-resistant tuberculosis patients and trends-over-time analysis of national surveillance data in Gabon, Central Africa.
    Abdul JBPAA; Adegbite BR; Ndanga MED; Edoa JR; Mevyann RC; Mfoumbi GRAI; de Dieu TJ; Mahoumbou J; Biyogho CM; Jeyaraj S; Niemann S; Lell B; Kremsner PG; Alabi AS; Adegnika AA; Grobusch MP
    Infection; 2023 Jun; 51(3):697-704. PubMed ID: 36307576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical research in the treatment of tuberculosis: current status and future prospects.
    Chang KC; Yew WW; Sotgiu G
    Int J Tuberc Lung Dis; 2015 Dec; 19(12):1417-27. PubMed ID: 26614181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TB-EFI, a novel 18-Plex microbead-based method for prediction of second-line drugs and ethambutol resistance in Mycobacterium tuberculosis complex.
    Klotoe BJ; Molina-Moya B; Gomes HM; Gomgnimbou MK; Oliveira Suzarte L; Féres Saad MH; Ali S; Dominguez J; Pimkina E; Zholdybayeva E; Sola C; Refrégier G
    J Microbiol Methods; 2018 Sep; 152():10-17. PubMed ID: 29913189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transmission and Drug Resistance Genotype of Multidrug-Resistant or Rifampicin-Resistant Mycobacterium tuberculosis in Chongqing, China.
    Zhao B; Liu C; Fan J; Ma A; He W; Hu Y; Zhao Y
    Microbiol Spectr; 2022 Oct; 10(5):e0240521. PubMed ID: 36214695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011.
    Ulmasova DJ; Uzakova G; Tillyashayhov MN; Turaev L; van Gemert W; Hoffmann H; Zignol M; Kremer K; Gombogaram T; Gadoev J; du Cros P; Muslimova N; Jalolov A; Dadu A; de Colombani P; Telnov O; Slizkiy A; Kholikulov B; Dara M; Falzon D
    Euro Surveill; 2013 Oct; 18(42):. PubMed ID: 24176581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000-2016.
    Oliveira O; Gaio R; Correia-Neves M; Rito T; Duarte R
    PLoS One; 2021; 16(4):e0250028. PubMed ID: 33878119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.